# Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis

> **NCT00367640** · PHASE2,PHASE3 · COMPLETED · sponsor: **Stallergenes Greer** · enrollment: 628 (actual)

## Conditions studied

- Allergy

## Interventions

- **DRUG:** 100 IR grass pollen allergen extract tablet
- **DRUG:** 300 IR grass pollen allergen extract tablet
- **DRUG:** 500 IR grass pollen allergen extract tablet
- **DRUG:** Placebo tablet

## Key facts

- **NCT ID:** NCT00367640
- **Lead sponsor:** Stallergenes Greer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2005-09
- **Final completion:** 2005-09
- **Target enrollment:** 628 (ACTUAL)
- **Last updated:** 2016-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00367640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00367640, "Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00367640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*